HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nami Ota Selected Research

gemeprost

4/2022Risk factors of retained products of conception after miscarriage or termination with gemeprost in the second trimester of pregnancy: a retrospective case-controlled study in Japanese population.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nami Ota Research Topics

Disease

3Neoplasms (Cancer)
11/2021 - 09/2016
2Uterine Cervical Neoplasms (Cancer of the Cervix)
03/2019 - 09/2016
1Spontaneous Abortion (Miscarriage)
04/2022
1Melanoma (Melanoma, Malignant)
11/2021
1Teratoma (Teratoid Tumor)
12/2018
1Neoplasm Metastasis (Metastasis)
01/2017
1Endometrial Neoplasms (Endometrial Cancer)
10/2016
1Carcinosarcoma
10/2016
1Adenocarcinoma
11/2015
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2015

Drug/Important Bio-Agent (IBA)

2Indicators and Reagents (Reagents)IBA
10/2016 - 09/2016
1gemeprostIBA
04/2022
1pembrolizumabIBA
11/2021
1Immune Checkpoint InhibitorsIBA
11/2021
1Dihydrotachysterol (AT 10)IBA
11/2021
1Dacarbazine (DIC)FDA LinkGeneric
01/2017
1Biomarkers (Surrogate Marker)IBA
10/2016

Therapy/Procedure

2Hysterectomy
09/2016 - 11/2015
2Lymph Node Excision (Lymph Node Dissection)
09/2016 - 11/2015
1Surgical Instruments (Clip)
04/2022
1Chemoradiotherapy
03/2019
1Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
03/2019
1Cystectomy
12/2018
1Adjuvant Chemotherapy
01/2017